Compare Fulford India with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FULFORD INDIA vs AJANTA PHARMA - Comparison Results

FULFORD INDIA     Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FULFORD INDIA AJANTA PHARMA FULFORD INDIA/
AJANTA PHARMA
 
P/E (TTM) x 398.8 28.3 1,407.6% View Chart
P/BV x 6.2 7.9 79.0% View Chart
Dividend Yield % 0.1 0.4 18.9%  

Financials

 FULFORD INDIA   AJANTA PHARMA
EQUITY SHARE DATA
    FULFORD INDIA
Mar-14
AJANTA PHARMA
Mar-19
FULFORD INDIA/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs9421,422 66.2%   
Low Rs450898 50.1%   
Sales per share (Unadj.) Rs691.4233.5 296.1%  
Earnings per share (Unadj.) Rs11.544.0 26.1%  
Cash flow per share (Unadj.) Rs15.452.2 29.4%  
Dividends per share (Unadj.) Rs2.009.00 22.2%  
Dividend yield (eoy) %0.30.8 37.0%  
Book value per share (Unadj.) Rs380.0255.1 149.0%  
Shares outstanding (eoy) m3.9088.02 4.4%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x1.05.0 20.3%   
Avg P/E ratio x60.726.4 230.2%  
P/CF ratio (eoy) x45.322.2 203.8%  
Price / Book Value ratio x1.84.5 40.3%  
Dividend payout %17.420.5 85.2%   
Avg Mkt Cap Rs m2,714102,081 2.7%   
No. of employees `0000.46.8 6.5%   
Total wages/salary Rs m5054,307 11.7%   
Avg. sales/employee Rs Th6,073.03,022.6 200.9%   
Avg. wages/employee Rs Th1,137.4633.4 179.6%   
Avg. net profit/employee Rs Th100.7569.1 17.7%   
INCOME DATA
Net Sales Rs m2,69620,554 13.1%  
Other income Rs m125211 59.5%   
Total revenues Rs m2,82220,765 13.6%   
Gross profit Rs m-465,664 -0.8%  
Depreciation Rs m15721 2.1%   
Interest Rs m1012 81.9%   
Profit before tax Rs m545,143 1.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m101,273 0.8%   
Profit after tax Rs m453,870 1.2%  
Gross profit margin %-1.727.6 -6.2%  
Effective tax rate %17.724.8 71.4%   
Net profit margin %1.718.8 8.8%  
BALANCE SHEET DATA
Current assets Rs m1,73811,812 14.7%   
Current liabilities Rs m5453,776 14.4%   
Net working cap to sales %44.339.1 113.2%  
Current ratio x3.23.1 102.0%  
Inventory Days Days4877 62.6%  
Debtors Days Days482 5.3%  
Net fixed assets Rs m1214,398 0.1%   
Share capital Rs m39175 22.2%   
"Free" reserves Rs m1,44322,277 6.5%   
Net worth Rs m1,48222,452 6.6%   
Long term debt Rs m07 0.0%   
Total assets Rs m2,07726,962 7.7%  
Interest coverage x6.7444.3 1.5%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.30.8 170.3%   
Return on assets %2.614.4 18.1%  
Return on equity %3.017.2 17.5%  
Return on capital %4.323.0 18.8%  
Exports to sales %00-   
Imports to sales %24.50-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m659NA-   
Fx inflow Rs m1710,682 0.2%   
Fx outflow Rs m6732,102 32.0%   
Net fx Rs m-6568,580 -7.6%   
CASH FLOW
From Operations Rs m903,748 2.4%  
From Investments Rs m105-2,228 -4.7%  
From Financial Activity Rs m-14-1,475 1.0%  
Net Cashflow Rs m18145 399.3%  

Share Holding

Indian Promoters % 0.0 73.8 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 3.8 1.6 245.2%  
FIIs % 0.1 7.6 1.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.2 17.0 124.7%  
Shareholders   4,783 20,968 22.8%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FULFORD INDIA With:   ALEMBIC  AUROBINDO PHARMA  STERLING BIOTECH  GLENMARK PHARMA  SUN PHARMA  

Compare FULFORD INDIA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Maruti Extends Production Shutdown, Avenue Supermarts Q4 Results, and Buzzing Stocks Today(Pre-Open)

Indian share markets ended higher yesterday. At the closing bell yesterday, the BSE Sensex stood higher by 296 points (up 0.6%).

Related Views on News

AJANTA PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 64.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 64.2% YoY). Sales on the other hand came in at Rs 7 bn (up 15.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 28.9% (Quarterly Result Update)

Aug 24, 2020 | Updated on Aug 24, 2020

For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 45.3% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 45.3% YoY). Sales on the other hand came in at Rs 7 bn (up 32.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 60.8% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 60.8% YoY). Sales on the other hand came in at Rs 7 bn (up 34.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

FULFORD INDIA SHARE PRICE


Jul 30, 2015 (Close)

TRACK FULFORD INDIA

  • Track your investment in FULFORD INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

FULFORD INDIA - PROCTER & GAMBLE HEALTH COMPARISON

COMPARE FULFORD INDIA WITH

MARKET STATS